Annals of Pediatric Endocrinology & Metabolism最新文献_第3页

Association between cannabis use and risk of gynecomastia: commentary on "Gynecomastia in adolescent males: current understanding of its etiology, pathophysiology, diagnosis, and treatment". 大麻使用与男性乳房发育风险之间的关系。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-01-15 DOI: 10.6065/apem.2448152.076

Jia-Lin Wu, Jun-Yang Luo, Xin-Yi Deng, Zai-Bo Jiang

引用次数: 0

Commentary on "Pediatric and adult osteoporosis: a contrasting mirror". 评论“儿童和成人骨质疏松症：一面对比鲜明的镜子”。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2448244.122

Yoon-Sok Chung

引用次数: 0

Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations. 儿童生长激素缺乏症中的生长激素：临床试验和现实世界考虑的综合综述。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2448258.129

Aristides K Maniatis, Michael P Wajnrajch, Marc Thomas, Sung Beom Chung, Jieun Lee

{"title":"Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations.","authors":"Aristides K Maniatis, Michael P Wajnrajch, Marc Thomas, Sung Beom Chung, Jieun Lee","doi":"10.6065/apem.2448258.129","DOIUrl":"10.6065/apem.2448258.129","url":null,"abstract":"Growth hormone (GH) is crucial for childhood growth and body composition. In pediatric GH deficiency (pGHD), the pituitary gland fails to produce sufficient GH, which affects linear growth in childhood. pGHD is conventionally treated with daily recombinant human GH (rhGH); however, because GH therapy lasts throughout childhood, adherence to daily rhGH treatment can be low, resulting in suboptimal effectiveness. Somatrogon is a long-acting GH analog designed to address the challenges associated with daily GH therapy for pGHD. Somatrogon administered once per week is a potential alternative to daily GH therapy. The use of somatrogon is supported by phase II and III clinical trials demonstrating that once-weekly injections are noninferior to once-daily somatropin injections in terms of efficacy, safety, and tolerability and have the advantage of reduced treatment burden. This review summarizes the clinical trials of somatrogon and discusses the therapeutic profile and effects of treating pGHD with reduced injection frequency.","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"30 1","pages":"11-16"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11917396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic challenges of Allan-Herndon-Dudley syndrome: a case of hypothyroidism and developmental delay. Allan-Herndon-Dudley综合征的诊断挑战：甲状腺功能减退和发育迟缓1例。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2448032.016

Eun Young Joo, Myung Ji Yoo, Ji-Eun Lee, Su Jin Kim

引用次数: 0

Reply to commentary on "Gynecomastia in adolescent males: current understanding of its etiology, pathophysiology, diagnosis, and treatment". 回复关于“青春期男性男性乳房发育症：目前对其病因、病理生理、诊断和治疗的认识”的评论。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2550032.016

Kotb Abbass Metwalley

引用次数: 0

Commentary on "Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations". 对“儿童生长激素缺乏症中的生长激素：临床试验和现实世界考虑的综合回顾”的评论。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2524129edi01

Yoo-Mi Kim

引用次数: 0

Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty. 促性腺激素释放激素激动剂治疗女孩中枢性性早熟的长期疗效。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2448038.019

Jung Hwangbo, Eungu Kang, Hyo-Kyoung Nam, Young-Jun Rhie, Kee-Hyoung Lee

{"title":"Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty.","authors":"Jung Hwangbo, Eungu Kang, Hyo-Kyoung Nam, Young-Jun Rhie, Kee-Hyoung Lee","doi":"10.6065/apem.2448038.019","DOIUrl":"10.6065/apem.2448038.019","url":null,"abstract":"Purpose: This study aimed to examine the effects of gonadotropin-releasing hormone agonist (GnRHa) treatment on final height outcomes in girls with idiopathic central precocious puberty (CPP) from the start of treatment to their postmenarche visit.Methods: We conducted a retrospective analysis of 200 girls with idiopathic CPP who received GnRHa therapy, focusing on auxological and clinical outcomes at treatment initiation, treatment completion, and the last, postmenarche visit.Results: The mean chronological age (CA) at GnRHa treatment initiation was 8.24±0.73 years. The mean duration of GnRHa treatment was 3.12±0.81 years. The average age at menarche was 12.73±0.56 years, occurring a mean of 17.15±5.52 months after completing GnRHa therapy. The predicted adult height (PAH) standard deviation score (SDS) after menarche (0.48±0.99) was significantly greater than before treatment (-1.33±1.46) (P<0.001). Factors including greater bone age advancement (P<0.001), lower height SDS for CA at treatment initiation (P<0.001), and higher midparental height SDS (P=0.001) were positively associated with an increase in PAH SDS at the last visit. However, near-final height and the increase in PAH SDS at the last visit were not significantly different between patients who received early treatment (<8 years) and those who received later treatment (8-9 years).Conclusion: GnRHa treatment improved the final height outcomes in all girls with CPP, including those treated between 8 and 9 years of age.","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"30 1","pages":"31-37"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11917394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric thyroid cancer: key considerations based on the 2024 Korean Thyroid Association Differentiated Thyroid Cancer Management Guidelines. 儿童甲状腺癌：基于2024年韩国甲状腺协会甲状腺癌管理指南的关键考虑因素。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-01-06 DOI: 10.6065/apem.2448296.148

Eun Kyung Lee, Young Ah Lee

引用次数: 0

Control of T-cell immunity by fatty acid metabolism. 脂肪酸代谢对t细胞免疫的控制。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2024-12-01 Epub Date: 2024-12-31 DOI: 10.6065/apem.2448160.080

Jaemin Kim, Yoosun Lee, Yeonseok Chung

引用次数: 0

Pituitary abnormalities in patients with pediatric growth hormone deficiency in a single tertiary center. 儿童生长激素缺乏症患者的垂体异常在单一三级中心。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2024-12-01 Epub Date: 2024-12-31 DOI: 10.6065/apem.2448070.035

Hyeon Jun Jung, Jeong Rye Kim, Jeesuk Yu

{"title":"Pituitary abnormalities in patients with pediatric growth hormone deficiency in a single tertiary center.","authors":"Hyeon Jun Jung, Jeong Rye Kim, Jeesuk Yu","doi":"10.6065/apem.2448070.035","DOIUrl":"10.6065/apem.2448070.035","url":null,"abstract":"Purpose: There is controversy as to whether brain magnetic resonance imaging (MRI) should be performed on all children with growth hormone deficiency (GHD) including those judged to have mild GHD. This study was aimed to determine the frequency of pituitary or intracranial abnormalities in pediatric GHD and to identify risk factors that may predict pituitary or intracranial abnormalities.Methods: A total of 95 pediatric GHD patients were included. Their medical records and brain magnetic resonance (MR) images were reviewed retrospectively.Results: Abnormal pathogenic MR images were found in 14 patients (14.7%), including 10 (10.5%) with pituitary hypoplasia and 4 (4.2%) with pituitary stalk interruption syndrome. Serum levels of insulin-like growth factor-I (IGF-I), IGF-I standard deviation score (SDS), insulin-like growth factor binding protein 3 (IGFBP3), and growth hormone (GH) peak level of GH stimulation test were statistically significantly lower in the group with abnormal brain MRI. The frequency of abnormal MRI was statistically significantly higher in the complete GHD group. IGF-1 SDS showed the highest area under the curve which can predict the presence of brain abnormality with a sensitivity of 85% and a specificity of 71.4%, if IGF-1 SDS was less than -1.365. IGF-1, IGFBP3, and GH peak levels also showed good sensitivity of over 80% for predicting brain abnormalities with cutoff values of 70.285 ng/mL, 1,604 ng/mL, and 4.205 ng/mL, respectively.Conclusion: The sensitivity and specificity of each cutoff value of IGF-1, IGF-1 SDS, IGFBP3, and GH peak levels were good and statistically significant in predicting brain MRI abnormalities. However, it was insufficient to predict all brain abnormalities with these variables. Therefore, we would like to recommend performing a brain MRI if a child is diagnosed with GHD.","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"29 6","pages":"365-370"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0